Comparative Pharmacology
Head-to-head clinical analysis: MESTINON versus MYTELASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MESTINON versus MYTELASE.
MESTINON vs MYTELASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
None Documented
None Documented
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor